Ahmadi S, Rahimian E, Rahimi S, Zarandi B, Bahraini M, Soleymani M
Biomark Res. 2024; 12(1):137.
PMID: 39538363
PMC: 11565275.
DOI: 10.1186/s40364-024-00676-9.
Sager R, Backe S, Neckers L, Woodford M, Mollapour M
Methods Mol Biol. 2023; 2693:125-139.
PMID: 37540432
PMC: 10518168.
DOI: 10.1007/978-1-0716-3342-7_11.
Fu J, Zheng S, Wang Y, Hu X, Xiao Y, Wang J
Proc Natl Acad Sci U S A. 2023; 120(31):e2221522120.
PMID: 37487085
PMC: 10400967.
DOI: 10.1073/pnas.2221522120.
Synoradzki K, Bartnik E, Czarnecka A, Fiedorowicz M, Firlej W, Brodziak A
Cancers (Basel). 2021; 13(17).
PMID: 34503094
PMC: 8428337.
DOI: 10.3390/cancers13174284.
Gomes A, Ramos H, Inga A, Sousa E, Saraiva L
Cancers (Basel). 2021; 13(13).
PMID: 34283062
PMC: 8268744.
DOI: 10.3390/cancers13133344.
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.
Hernandez Borrero L, El-Deiry W
Biochim Biophys Acta Rev Cancer. 2021; 1876(1):188556.
PMID: 33932560
PMC: 8730328.
DOI: 10.1016/j.bbcan.2021.188556.
Structure, Function, and Regulation of the Hsp90 Machinery.
Biebl M, Buchner J
Cold Spring Harb Perspect Biol. 2019; 11(9).
PMID: 30745292
PMC: 6719599.
DOI: 10.1101/cshperspect.a034017.
Gain of UBE2D1 facilitates hepatocellular carcinoma progression and is associated with DNA damage caused by continuous IL-6.
Zhou C, Bi F, Yuan J, Yang F, Sun S
J Exp Clin Cancer Res. 2018; 37(1):290.
PMID: 30482241
PMC: 6260761.
DOI: 10.1186/s13046-018-0951-8.
The interplay between mutant p53 and the mevalonate pathway.
Parrales A, Thoenen E, Iwakuma T
Cell Death Differ. 2017; 25(3):460-470.
PMID: 29238070
PMC: 5864191.
DOI: 10.1038/s41418-017-0026-y.
Detecting Posttranslational Modifications of Hsp90.
Sager R, Woodford M, Neckers L, Mollapour M
Methods Mol Biol. 2017; 1709:209-219.
PMID: 29177662
PMC: 6376113.
DOI: 10.1007/978-1-4939-7477-1_16.
The HSP90 chaperone machinery.
Schopf F, Biebl M, Buchner J
Nat Rev Mol Cell Biol. 2017; 18(6):345-360.
PMID: 28429788
DOI: 10.1038/nrm.2017.20.
HSP90 inhibitors in the context of heat shock and the unfolded protein response: effects on a primary canine pulmonary adenocarcinoma cell line.
Graner A, Hellwinkel J, Lencioni A, Madsen H, Harland T, Marchando P
Int J Hyperthermia. 2016; 33(3):303-317.
PMID: 27829290
PMC: 5675827.
DOI: 10.1080/02656736.2016.1256503.
The Mechanism of Hsp90 ATPase Stimulation by Aha1.
Wolmarans A, Lee B, Spyracopoulos L, LaPointe P
Sci Rep. 2016; 6:33179.
PMID: 27615124
PMC: 5018835.
DOI: 10.1038/srep33179.
The Paradox of p53: What, How, and Why?.
Aylon Y, Oren M
Cold Spring Harb Perspect Med. 2016; 6(10).
PMID: 27413116
PMC: 5046691.
DOI: 10.1101/cshperspect.a026328.
Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier.
Garcia P, Seiva F, Carniato A, de Mello Junior W, Duran N, Macedo A
BMC Cancer. 2016; 16:422.
PMID: 27389279
PMC: 4937612.
DOI: 10.1186/s12885-016-2474-z.
Human, vector and parasite Hsp90 proteins: A comparative bioinformatics analysis.
Faya N, Penkler D, Tastan Bishop O
FEBS Open Bio. 2016; 5:916-27.
PMID: 26793431
PMC: 4688443.
DOI: 10.1016/j.fob.2015.11.003.
Targeting Oncogenic Mutant p53 for Cancer Therapy.
Parrales A, Iwakuma T
Front Oncol. 2016; 5:288.
PMID: 26732534
PMC: 4685147.
DOI: 10.3389/fonc.2015.00288.
Regulation of Greatwall kinase by protein stabilization and nuclear localization.
Yamamoto T, Wang L, Fisher L, Eckerdt F, Peng A
Cell Cycle. 2014; 13(22):3565-75.
PMID: 25483093
PMC: 4612739.
DOI: 10.4161/15384101.2014.962942.
Functions of the Hsp90 chaperone system: lifting client proteins to new heights.
Eckl J, Richter K
Int J Biochem Mol Biol. 2014; 4(4):157-65.
PMID: 24380020
PMC: 3867702.
HSP90 Inhibitors, Geldanamycin and Radicicol, Enhance Fisetin-Induced Cytotoxicity via Induction of Apoptosis in Human Colonic Cancer Cells.
Wu M, Lien G, Shen S, Yang L, Chen Y
Evid Based Complement Alternat Med. 2013; 2013:987612.
PMID: 23840275
PMC: 3693119.
DOI: 10.1155/2013/987612.